Analysis of AR-FL and AR-V1 in Whole Blood of Patients with Castration Resistant Prostate Cancer As a Tool for Predicting Response to Abiraterone Acetate

Overview

Journal J Urol

Publisher Wolters Kluwer

Specialty Urology

Date 2020 Feb 19

PMID 32068491

Citations 6

Authors

Kristina Stuopelyte

Rasa Sabaliauskaite

Arnas Bakavicius

Benedikta S Haflidadottir

Tapio Visakorpi

Riina-Minna Vaananen

Chintan Patel

Daniel C Danila

Hans Lilja

Juozas R Lazutka

Albertas Ulys

Feliksas Jankevicius

Sonata Jarmalaite

Affiliations

Soon will be listed here.

Abstract

Purpose: Reliable molecular diagnostic tools are still unavailable for making informed treatment decisions and monitoring the response in patients with castration resistant prostate cancer. We evaluated the significance of whole blood circulating androgen receptor transcripts of full length (AR-FL) and splice variants (AR-V1, AR-V3 and AR-V7) as biomarkers of abiraterone acetate treatment resistance in patients with castration resistant prostate cancer.

Materials And Methods: After retrospective analysis in 112 prostate specimens AR-FL, AR-V1, AR-V3 and AR-V7 were evaluated in 185 serial blood samples, prospectively collected from 102 patients with castration resistant prostate cancer before and during abiraterone acetate therapy via reverse transcription quantitative polymerase chain reaction.

Results: AR-FL was present in all samples while AR-V1, AR-V3, AR-V7 and at least 1 of them was detected in 17%, 55%, 65% and 81% of castration resistant prostate cancer blood samples, respectively. The highest amount of AR-V1 was found in blood of patients whose response time was short and medium in comparison to extended. Patients with a higher level of AR-FL and/or AR-V1 had the shortest progression-free survival and overall survival (p <0.0001).

Conclusions: Blood circulating AR-FL or AR-V1 can serve as blood based biomarkers for identification of the primary resistance to abiraterone acetate and the tool to monitor de novo resistance development during abiraterone acetate treatment.

Citing Articles

An MRI radiomics model for predicting a prostate-specific antigen response following abiraterone treatment in patients with metastatic castration-resistant prostate cancer.

Wu Y, Liu X, Chen S, Fang F, Shi F, Xia Y Front Oncol. 2025; 15:1491848.

PMID: 39931089 PMC: 11807802. DOI: 10.3389/fonc.2025.1491848.

Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers.

Chrenkova E, Studentova H, Hola K, Kahounova Z, Hendrychova R, Soucek K Front Oncol. 2024; 14:1394292.

PMID: 39319053 PMC: 11420116. DOI: 10.3389/fonc.2024.1394292.

A Compendium of AR Splice Variants in Metastatic Castration-Resistant Prostate Cancer.

Isebia K, Lolkema M, Jenster G, de Wit R, Martens J, van Riet J Int J Mol Sci. 2023; 24(6).

PMID: 36983083 PMC: 10053078. DOI: 10.3390/ijms24066009.

Genetic profiling of hormone-sensitive and castration-resistant prostate cancers and identification of genetic mutations prone to castration-resistant prostate cancer.

Wang Z, Yan X, Tang P, Tang T, Wang Y, Peng S Prostate Cancer Prostatic Dis. 2022; 26(1):180-187.

PMID: 36401126 DOI: 10.1038/s41391-022-00618-2.

Liquid biopsy-based targeted gene screening highlights tumor cell subtypes in patients with advanced prostate cancer.

Derderian S, Vesval Q, Wissing M, Hamel L, Cote N, Vanhuyse M Clin Transl Sci. 2022; 15(11):2597-2612.

PMID: 36172886 PMC: 9652435. DOI: 10.1111/cts.13372.

References

Liu X, Ledet E, Li D, Dotiwala A, Steinberger A, Feibus A . A Whole Blood Assay for AR-V7 and AR in Patients with Prostate Cancer. J Urol. 2016; 196(6):1758-1763. PMC: 5161406. DOI: 10.1016/j.juro.2016.06.095. View

Hu R, Dunn T, Wei S, Isharwal S, Veltri R, Humphreys E . Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009; 69(1):16-22. PMC: 2614301. DOI: 10.1158/0008-5472.CAN-08-2764. View

Sabaliauskaite R, Jarmalaite S, Petroska D, Dasevicius D, Laurinavicius A, Jankevicius F . Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer. Genes Chromosomes Cancer. 2012; 51(8):781-91. DOI: 10.1002/gcc.21963. View

To S, Kwan E, Fettke H, Mant A, Docanto M, Martelotto L . Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2018; 73(6):818-821. DOI: 10.1016/j.eururo.2018.01.007. View

Antonarakis E . Current understanding of resistance to abiraterone and enzalutamide in advanced prostate cancer. Clin Adv Hematol Oncol. 2016; 14(5):316-9. View

de Bono J, Logothetis C, Molina A, Fizazi K, North S, Chu L . Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364(21):1995-2005. PMC: 3471149. DOI: 10.1056/NEJMoa1014618. View

Luo J, Attard G, Balk S, Bevan C, Burnstein K, Cato L . Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Eur Urol. 2017; 73(5):715-723. PMC: 5929166. DOI: 10.1016/j.eururo.2017.11.038. View

Seitz A, Thoene S, Bietenbeck A, Nawroth R, Tauber R, Thalgott M . AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide. Eur Urol. 2017; 72(5):828-834. DOI: 10.1016/j.eururo.2017.07.024. View

Antonarakis E, Lu C, Wang H, Luber B, Nakazawa M, Roeser J . AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014; 371(11):1028-38. PMC: 4201502. DOI: 10.1056/NEJMoa1315815. View

10.

Dehm S, Schmidt L, Heemers H, Vessella R, Tindall D . Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008; 68(13):5469-77. PMC: 2663383. DOI: 10.1158/0008-5472.CAN-08-0594. View

11.

Sun S, Sprenger C, Vessella R, Haugk K, Soriano K, Mostaghel E . Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest. 2010; 120(8):2715-30. PMC: 2912187. DOI: 10.1172/JCI41824. View

12.

Ryan C, Shore N, Concepcion R . A urologic oncology roundtable discussion: how to choose among the available therapies for the treatment of castration-resistant prostate cancer. Postgrad Med. 2013; 125(6):114-6. DOI: 10.3810/pgm.2013.11.2718. View

13.

Qu F, Xie W, Nakabayashi M, Zhang H, Jeong S, Wang X . Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer. Clin Cancer Res. 2016; 23(3):726-734. PMC: 5675562. DOI: 10.1158/1078-0432.CCR-16-1070. View

14.

Danila D, Anand A, Schultz N, Heller G, Wan M, Sung C . Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival. Eur Urol. 2013; 65(6):1191-7. PMC: 4113474. DOI: 10.1016/j.eururo.2013.07.006. View

15.

Tilki D, Schaeffer E, Evans C . Understanding Mechanisms of Resistance in Metastatic Castration-resistant Prostate Cancer: The Role of the Androgen Receptor. Eur Urol Focus. 2017; 2(5):499-505. DOI: 10.1016/j.euf.2016.11.013. View

16.

Guo Z, Yang X, Sun F, Jiang R, Linn D, Chen H . A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 2009; 69(6):2305-13. PMC: 2672822. DOI: 10.1158/0008-5472.CAN-08-3795. View

17.

Takeuchi T, Okuno Y, Hattori-Kato M, Zaitsu M, Mikami K . Detection of AR-V7 mRNA in whole blood may not predict the effectiveness of novel endocrine drugs for castration-resistant prostate cancer. Res Rep Urol. 2016; 8:21-5. PMC: 4734820. DOI: 10.2147/RRU.S98877. View

18.

Drimer Berg K, Thomsen F, Mikkelsen M, Ingimarsdottir I, Hansen R, Kejs A . Improved survival for patients with de novo metastatic prostate cancer in the last 20 years. Eur J Cancer. 2016; 72:20-27. DOI: 10.1016/j.ejca.2016.11.025. View

19.

Daniunaite K, Jarmalaite S, Kalinauskaite N, Petroska D, Laurinavicius A, Lazutka J . Prognostic value of RASSF1 promoter methylation in prostate cancer. J Urol. 2014; 192(6):1849-55. DOI: 10.1016/j.juro.2014.06.075. View

20.

Saylor P, Lee R, Arora K, Deshpande V, Hu R, Olivier K . Branched Chain RNA In Situ Hybridization for Androgen Receptor Splice Variant AR-V7 as a Prognostic Biomarker for Metastatic Castration-Sensitive Prostate Cancer. Clin Cancer Res. 2016; 23(2):363-369. DOI: 10.1158/1078-0432.CCR-16-0237. View